These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 16213066)
1. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. de Bruyn G; Vargas-Cortez M; Warren T; Tyring SK; Fife KH; Lalezari J; Brady RC; Shahmanesh M; Kinghorn G; Beutner KR; Patel R; Drehobl MA; Horner P; Kurtz TO; McDermott S; Wald A; Corey L Vaccine; 2006 Feb; 24(7):914-20. PubMed ID: 16213066 [TBL] [Abstract][Full Text] [Related]
2. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes. Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071 [TBL] [Abstract][Full Text] [Related]
3. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients. Fife KH; Warren TJ; Justus SE; Heitman CK; Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016 [TBL] [Abstract][Full Text] [Related]
4. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. Wald A; Zeh J; Selke S; Warren T; Ryncarz AJ; Ashley R; Krieger JN; Corey L N Engl J Med; 2000 Mar; 342(12):844-50. PubMed ID: 10727588 [TBL] [Abstract][Full Text] [Related]
5. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection. Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859 [TBL] [Abstract][Full Text] [Related]
6. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. Kim HN; Wald A; Harris J; Almekinder J; Heitman C; Corey L Sex Transm Dis; 2008 Feb; 35(2):124-8. PubMed ID: 17921912 [TBL] [Abstract][Full Text] [Related]
7. Reducing the risk of transmitting genital herpes: advances in understanding and therapy. Leone P Curr Med Res Opin; 2005 Oct; 21(10):1577-82. PubMed ID: 16238897 [TBL] [Abstract][Full Text] [Related]
14. Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men. Kim HN; Meier A; Huang ML; Kuntz S; Selke S; Celum C; Corey L; Wald A J Infect Dis; 2006 Aug; 194(4):420-7. PubMed ID: 16845624 [TBL] [Abstract][Full Text] [Related]
15. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life. Handsfield HH; Warren T; Werner M; Phillips JA Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847 [TBL] [Abstract][Full Text] [Related]
17. [Herpes simplex virus vaccine studies: from past to present]. Us D Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702 [TBL] [Abstract][Full Text] [Related]
18. Isolation of herpes simplex virus from the genital tract during symptomatic recurrence on the buttocks. Kerkering K; Gardella C; Selke S; Krantz E; Corey L; Wald A Obstet Gynecol; 2006 Oct; 108(4):947-52. PubMed ID: 17012458 [TBL] [Abstract][Full Text] [Related]
19. An update on short-course episodic and prevention therapies for herpes genitalis. Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886 [TBL] [Abstract][Full Text] [Related]
20. The Holy Grail: immune control of human herpes simplex virus infection and disease. Cunningham AL; Mikloska Z Herpes; 2001 Mar; 8 Suppl 1():6A-10A. PubMed ID: 11867028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]